HHS Unveils New Vaccine Injury Research Push Under Kennedy
The Department of Health and Human Services has launched a broad initiative to expand vaccine injury surveillance, research, and reporting, pairing a new National Institutes of Health clinic with updates to the federal adverse-event system and financial incentives for physicians who file reports. The plan lands in one of the most politically charged corners of U.S. health policy: the effort to examine rare post-vaccination symptoms while preserving confidence in immunization as a core public health tool.
At the center of the program is a clinic the NIH opened in Bethesda, Maryland, on Oct. 5. Researchers there will investigate potential causes of health problems following vaccination, building a setting specifically designed for patients who believe their symptoms began after immunization. HHS says the broader objective is to improve how the federal government identifies, documents, investigates and responds to health problems reported after vaccination, while also gathering better evidence about possible vaccine-related injuries.
The clinical and policy stakes are immediate. Vaccine surveillance systems work only when clinicians, patients and public agencies capture adverse events with enough consistency to separate coincidence from true causality. Rare events are easy to miss in routine care, yet they are also easy to over-attribute when a large population is vaccinated and many unrelated medical problems emerge by chance in the same time window.
Reporting Infrastructure Takes Center Stage
One pillar of the new approach is reimbursement for doctors who report suspected side effects to the Vaccine Adverse Event Reporting System, or VAERS. HHS framed the payment as a way to encourage more complete documentation, a practical response to a well-known limitation of passive surveillance: busy clinicians often do not submit reports unless they see a clear signal or are motivated to do the paperwork.
A second change targets the reporting platform itself. HHS plans to make VAERS more accessible, though the announcement did not provide technical details about what the redesign will include. A more usable system may lower the friction that keeps adverse events from being entered at all, especially when the event is nonspecific, delayed, or difficult to classify.
A third component pushes the burden of documentation into electronic health records. HHS will require EHRs to capture vaccine-related adverse events, a move that could make reporting more systematic and less dependent on individual memory or manual follow-up. In principle, better integration with routine clinical workflow can improve signal detection, because the data are recorded closer to the bedside and closer to the moment symptoms are recognized.
One sentence in the announcement carries the policy message plainly: the government wants a stronger evidence base for events that occur after vaccination. The harder question is how to build that evidence without inflaming confusion between a temporal association and a causal injury.
Kennedy Puts Vaccine Safety at the Center of HHS
HHS Secretary Robert F. Kennedy Jr. has made vaccine safety a defining part of his agenda, and the new initiative reflects that priority. In his statement, Kennedy said the government must listen to patients and families who report vaccine injuries rather than dismiss or “gaslight” them, adding that he and President Donald Trump are building a health system that takes people seriously, follows the evidence and uses what is learned to make vaccines safer.
That framing resonates with patients who feel unheard after symptoms arise, especially when their concerns are complex, poorly understood, or dismissed too quickly. At the same time, vaccine research sits in a setting where language matters. Public health agencies have to acknowledge adverse events and investigate them rigorously without implying a risk profile that the underlying data do not support.
Vaccines remain among the most effective preventive interventions in medicine. They are widely credited with eradicating or sharply reducing diseases such as smallpox, measles and polio, and side effects are usually mild and short-lived. Severe complications can occur, but they are rare, and the overall balance of risk still favors immunization because infectious diseases themselves cause far more harm than vaccination in the vast majority of cases.
Expert Skepticism Follows the Announcement
Paul Offit, a vaccine expert and professor of pediatrics at the Children’s Hospital of Philadelphia, warned that the initiative could weaken rather than strengthen public confidence. He said Kennedy’s past record suggests he will continue to produce misleading, poorly performed studies that further shake parents’ confidence in vaccines, and that the only trust gained would come from anti-vaccine activists who accept false claims about vaccine safety.
Offit’s criticism points to a central tension in the new plan. A stronger reporting system can support better safety science when it is paired with careful analysis, transparent methods and disciplined interpretation. It can also magnify noise if reports are treated as proof of harm before investigators establish whether a vaccine, an underlying illness, or chance timing explains the event.
The distinction matters because vaccine safety research depends on credible denominators, careful case definitions and the ability to compare reported events with expected background rates. Without that structure, a reporting surge can look like a safety crisis even when the underlying risk has not changed.
HHS did not provide additional comment when contacted for more detail. News of the pending announcement had already circulated earlier through reporting by Science.
Policy Changes Arrive as Confidence in Vaccines Slips
The announcement arrives amid declining immunization rates in the U.S. and a rise in vaccine-preventable diseases, including measles. Those trends increase the importance of surveillance that is accurate enough to detect real harms and robust enough to avoid amplifying misinformation.
Kennedy’s influence has already reached the federal vaccine apparatus. Last year, he overhauled a key committee that shapes U.S. vaccine policy, and before legal challenges blocked parts of that effort, the panel advanced recommendations that weakened support for established vaccines and gave airtime to debunked theories about vaccine chemicals and chronic disease. Autism has also remained a focus of his public remarks, despite decades of research finding no association between vaccination and autism.
The childhood immunization schedule has been pulled into the dispute as well. A directive to slow that schedule was stayed in court, while Trump later signed an executive order reviving it. Those conflicts have fed public uncertainty at a time when steady pediatric vaccination is essential to keep outbreaks from gaining ground.
What emerges from the new HHS plan is not a settled scientific answer but a larger institutional bet: that better reporting, a new NIH clinic and more complete records will produce cleaner evidence about post-vaccination illness. The practical test will be whether the system distinguishes true vaccine injuries from coincidental medical events, and whether the government can investigate those cases without eroding trust in one of modern medicine’s most consequential preventive tools.